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Screening of a Novel Fragment Library with Functional
Complexity against Mycobacterium tuberculosis InhA
Federica Prati,[a, b] Fabio Zuccotto,[a] Daniel Fletcher,[a] Maire A. Convery,[c] Raquel Fernandez-
Menendez,[b] Robert Bates,[b] Lourdes Encinas,[b] Jingkun Zeng,[c] Chun-wa Chung,[c]
Paco De Dios Anton,[b] Alfonso Mendoza-Losana,[b] Claire Mackenzie,[a] Simon R. Green,[a]
Margaret Huggett,[a] David Barros,[b] Paul G. Wyatt,*[a] and Peter C. Ray*[a]
Our findings reported herein provide support for the benefits
of including functional group complexity (FGC) within frag-
ments when screening against protein targets such as Myco-
bacterium tuberculosis InhA. We show that InhA fragment ac-
tives with FGC maintained their binding pose during elabora-
tion. Furthermore, weak fragment hits with functional group
handles also allowed for facile fragment elaboration to afford
novel and potent InhA inhibitors with good ligand efficiency
metrics for optimization.
We recently reported on the design and synthesis of a novel
fragment library of diverse fragments which include functional
group complexity (FGC).[1] Functional groups,[2] or “chemical
handles”, were incorporated onto diverse scaffolds to allow for
additional interactions with target proteins with the aim of
maintaining binding poses during optimization, as well as aid
fragment elaboration.[1] However care has to be taken because
increasing complexity in a fragment decreases the probability
of it achieving optimal ligand-protein interactions.[3] Converse-
ly, too little complexity can lead to interesting interactions
being missed.[4] In this respect, fragment deconstruction stud-
ies on b-lactamase inhibitors,[5] suggest that small fragments
with “minimal complexity” derived from the deconstruction of
potent inhibitors do not always retain the binding poses of the
parent molecules. Whereas, fragments with built in FGC reca-
pitulate the larger potent inhibitor binding mode. Therefore, a
careful balance is required to identify a sweet spot of complex-
ity where detectable, single-mode binding of a ligand to a
target is most probable. There is further support for this con-
cept based on other fragment deconstruction case studies.[6]
Despite the molecular complexity model and its putative ap-
plications in fragment screening were introduced and refined
by Hann[3] and others over nearly two decades ago, to date
the authors are not aware of any reported fragment screening
against a novel diverse fragment library designed to include
FGC. Our recently reported FGC library is based on synthetic
chemistry toward selected functional groups.[1] However,
recent reports of an algorithm to identify all functional groups
in organic molecules, allows for the analysis of FGC in large
chemical databases of commercial fragments.[7]
Herein we describe the screening of such a library, in com-
parison with other fragment sets, against the highly validated
Mycobacterium tuberculosis (Mtb) target InhA.[8] Mtb is the
causative agent of tuberculosis (TB), which is currently the
leading infectious disease killer worldwide.[9] Isoniazid (INH,
Figure 1), a successful frontline TB drug for more than 50 years,
targets the NADH-dependent 2-trans enoyl–acyl carrier protein
Figure 1. INH and selected advanced direct InhA inhibitors 1–3.
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(ACP) reductase InhA. This is a key enzyme in the Mtb cell wall
synthesis pathway[10] and does not have a human orthologue.
The development of Mtb resistant strains to standard anti-TB
drugs,[11] including INH, necessitates the need for novel Mtb
targeted therapies. Resistance to INH develops mainly via mu-
tations in the Mtb KatG enzyme, which converts INH into an
acyl radical, which covalently binds to NADH and the resulting
adduct inhibits InhA.[12] Direct InhA inhibitors are envisaged to
bypass this resistance mechanism and maintain clinical efficacy.
Accordingly, there has been widespread research in this field[13]
and whilst limited set of potent direct InhA inhibitors with ac-
tivity against INH-resistant strains have been identified (1–3[14]
in Figure 1), none have been progressed into clinical develop-
ment. Hence, there remains a need to identify novel direct
InhA inhibitor scaffolds.
InhA inhibitors are known to modulate the tertiary structure
of the InhA protein binding pocket, in particular the substrate
binding loop (SBL).[15] In this respect, a fragment based (FB) ap-
proach[16] was considered appealing in order to assess the InhA
protein conformations for fragment actives and the structural
requirements for their optimization into potent InhA inhibitors.
For the above reasons, we screened the recently reported
FGC fragment library (FGC-FRAG),[1] as well as an informed
InhA commercial fragment set (InhA-INF-FRAG), which was
compiled based on the known direct InhA inhibitors in the
public domain (see Supporting Information). The above libra-
ries were screened alongside an historical commercial frag-
ment library (HIST-FRAG), a reported 3D fragment library (3D-
FRAG)[17] and fragments derived from inventory (INV-FRAG) and
project (PROJ-FRAG) sources. The overall library constituted
1360 fragments (Figure 2A), which were screened against the
NADH bound form of the InhA, using saturation transfer differ-
ence (STD) 1H NMR (complete results in Supporting Informa-
tion).
STD-NMR typically identifies ligands that bind weakly to
moderately to protein targets.[18] The criteria for a binding
event used here was a positive STD signal intensity which was
decreased by at least 50% on the addition of the known inhib-
itor 1 (R=Me).[14a] This resulted in 149 hits (11% hit rate). A
breakdown of these hits based on their source is given in Fig-
ure 2B. Due to its binding affinity being in the suitable range
(Kd5 mm),[19] NADH binding was also observed in the STD-
NMR spectra. It was noted that the stronger binders 1 (R=Me)
and 3 (R=CH2iPr)
[14b] decreased the STD-NMR intensities for
the NADH co-factor peaks. Therefore, greater importance was
given to those fragments which also caused a decrease in the
NADH STD peak intensities, as this was considered as evidence
of stronger binding. This further selection step decreased the
number of hits to 32 (4–35 in Figure 3; 2.4% hit rate). The pie
chart for the source of these 32 hits is given in Figure 2C. This
process increased the fraction of hits from the FGC-FRAG set
(29% to 41%). These data are interesting considering the FGC-
FRAG set only constituted 24% of the whole screening library.
The initial hit rate for the InhA-INF-FRAG set was low, although
the size of the library was small. This may be the result of a
lack of InhA fragment inhibitors that can be purchased from
vendors, as observed for deconstruction of kinase inhibitors
from the public domain.[20] The two hits derived from this li-
brary did, however, survive the second selection step and
could also be classified as FGC fragments. A high proportion of
project, historical derived and 3D fragment actives were also
noticeably enriched with FGC.
The 149 NMR hits were also screened in a high concentra-
tion (500 mm) biochemical assay. Only fragments 4 (13%), 9
(37%), 22 (11%), and 34 (10%) showed InhA inhibitory poten-
cies <10%, and were further tested in dose–response studies
up to 1 mm (Table 1). Notably, these four fragment hits were
all from the 32 compounds expected to be more potent based
on NADH STD signal suppression. Based on these results as
well as chemical diversity, 15 compounds were prioritized for
crystallography studies. Crystals suitable for structure determi-
nation were obtained for fragments 4, 9, 12, 22, 24 and 34
bound to InhA.
Surface plasmon resonance (SPR) equilibrium dissociation
binding constants (pKd) were also determined, and found to
correlate with InhA biochemical pIC50 values (Table 1).
Figure 2. A) Fragment screening library composition. B) 149 STD-NMR hits
vs. their source. C) 32 STD-NMR hits with reduction of NADH peak intensity
vs. their source.
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The InhA–NADH co-crystal structures for FGC fragments 22
(pIC50=3.1) and 24 (pIC50<3) were found to be in accordance
with the FGC-FRAG set design principle, in that additional in-
teractions were observed for their FG with the InhA protein
(Figures S1 and 4A). The co-crystal structure of 24 contains a
unique tetramer with four slightly different binding sites. The
following description is for one of these, details of the others
are shown in Figure S2). The amide carbonyl FG of 24 forms
an H-bond interaction with the InhA Tyr158 residue and the
NADH ribosyl-20-OH group, while the NH H-bonds with
Met199. Furthermore, the pyrimidine ring of 24 picks up an ad-
ditional H-bond interaction with the backbone NH of Met98, a
feature also observed for the thiadiazole core of a close ana-
logue (PDB ID: 4BQP) of advanced lead 2, which, however,
does not interact with Tyr158.[19] Whereas lead 3a (PDB ID:
4R9S) has a similar H-bond interaction with Tyr158 and the
NADH ribosyl-20-OH group. FGC fragment 24 is able to identify
distinct interactions associated with both leads 2 and 3a (Fig-
ure 4A).
Fragment 24 was found to overlay well with HIST-FRAG urea
12 (pIC50<3.0), with the embedded urea FG having similar in-
teractions with Tyr158, Met199 and the NADH ribosyl hydroxy
group (Figure 4A). Furthermore, the pyridyl group of 12 occu-
pies the same space as the lipophilic di-methyl cyclohexane
group in lead 3a (Figure S3), however, its nitrogen is predicted
to be protonated and binds to the carboxylic moiety of
Glu219. Overlay of the urea 12 with the amide 24 led to syn-
thesis of the merged amide 36 and urea 37 (Figure 5 and
Scheme S1). Amide 36 was inactive in the biochemical screen
(pIC50<3), but urea 37 had improved InhA biochemical poten-
Figure 3. 32 STD NMR hits 4–35. FGC are in blue; known InhA cores are in red. Crystal structures were obtained for fragments in bold.
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cy (pIC50=4.1) over parent fragments. The crystal structure of
InhA–NADH–ligand 37 complex indicated that the pose of the
individual fragment components was conserved (Figure 4B).
Preparation of 38, a simple methylated derivative of 12 result-
ed in improved enzymatic activity (pIC50=4.0), which trans-
ferred onto the pyrimidine series through synthesis of urea 39
(pIC50=5.0) (Figure 5 and Scheme S1). Advanced lead 3a was
overlaid with urea 37 (Figure S4), and the GSK inventory
searched to identify core fragment replacements of 3a. This
led to the identification of pyridinone 40[21] (Figure 5), with
good biochemical potency (pIC50=4.8). The co-crystal structure
of 40 showed the conserved functional groups overlaid with
both the advanced leads 3a and urea 37 (Figure S5). Replace-
ment of the phenyl group of 40 with the novel pyrimidine
fragment afforded compound 41 (Figure 5 and Scheme S2),
with improved enzymatic activity (pIC50=6.0). Once again, the
overall pose of the individual FGC fragment components of 40
and 41 was conserved (Figure 4C). The novel pyrimidines 42
and 43 (Figure 5 and Scheme S3) were also prepared, based
on 3a (pIC50=6.2), and showed good InhA biochemical poten-
cy (pIC50=6.5 and 5.2, respectively).
The interaction with Tyr158, previously described for the
urea and pyridone derivatives, is not present in the crystal
structures obtained for pyrazole fragment hits 4, 9 (Figure 6A)
and 34 (Figure 6B), as the Tyr158 side chain forms a water-
mediated bridge with NADH. However, the pyrazole rings
occupy the same sub-pocket, stack against the nicotinamide
ring of NADH, and the 2-N-pyrazole provides an H-bond inter-
action with the 20-OH group of NADH.
Fragment 9 is more potent in the biochemical screen
(pIC50=3.4) and its 5-NH2 group forms water-bridged interac-
tions with the NADH phosphate group as well as Met199 and
Thr196 (Figure 6A). In contrast, pyrazole 4 (pIC50<3) has a
slightly altered binding mode, where the hydroxy group has
an additional interaction with Met98 backbone NH (Figure 6A).
In accordance with previous fragment deconstruction stud-
ies,[2–3] the functionally complex InhA informed fragment 34
(pIC50<3) retains the binding pose observed for published ad-
vanced InhA lead 45[10c] (PDB ID: 5JFO, Figure 6B). The 3N of
the thiadiazole ring and NH side group of 34 and 45 H-bonds
with Met98 backbone.
Because good structural overlay (Figure S6) was observed
for 9 and the published InhA lead 44 (pIC50=6.9, PDB ID:
4QXM),[22] compound 46 (Figure 7 and Scheme S4) was synthe-
sized and showed good InhA activity (pIC50=6.3). Introducing
the amide FG results in movement of the phenyl group of 9 to
allow an additional H-bond interaction with Met98 backbone
CO (Figure 6C). Similarly, as a result of the deconstructed frag-
ment 34 retaining the binding pose of 45 (pIC50=8.1)
[14c] as
well as occupying the same pyrazole binding pocket as frag-
ment 9, compound 47 (Figure 7 and Scheme S5) was synthe-
sized. 47 showed good InhA activity (pIC50=7.3) and main-
tained the pose relative to 45 (Figure S7).
In conclusion, herein we report on the identification of
novel InhA fragment hits using STD-NMR screening, as well as
orthogonal InhA biochemical and SPR assays. High hit rates
were obtained from screening a recently reported novel frag-
ment set with built FGC versus other fragment sets. Notably,
starting from weakly active FGC fragments facilitated rapid
fragment based lead generation (FBLG) due to 1) easy chemi-
cal tractability and derivatization, 2) retention of the functional
group binding pose during fragment evolution through addi-
tional interactions with the target, which was confirmed by X-
ray studies. Conversely, elaboration of weakly bound InhA frag-
Table 1. Biochemical, SPR and LE metrics for fragment hits and optimized InhA inhibitors.
Compound InhA pIC50
[a][e] (% 500 mm) PDB ID SPR pKd
[f] InhA biochemical LE/LLE/LELP[c]
1 (R=Me) 7.9NA – ND 0.30/5.0/5.4
3 (R=CH2iPr) 5.00.7[d] – 4.40.07[a] 0.35/2.3/7.8
4 <3 (13%) 5OIC NA[a][g] –
9 3.40.23 (37%) 5OIF 3.30.08[a] 0.34/3.1/5.1
12 <3 (2%) 5OIL NA[a][g] –
22 3.10.05 (11%) 5OIM NA[a][g] 0.28/0.5/9.3
24 <3 (0%) 5OIN NA[a] –
34 <3 (10%) 5OIO ND –
36 <3 – ND –
37 4.10.06 5OIP NA[a][g] 0.24/3.4/6.2
38 4.00.01 – 3.20.10[a] 0.30/1.7/7.5
39 5.00.14 – 4.70.03[b] 0.30/4.2/6.5
40 4.80.20 5OIQ 4.60.02[a] 0.45/2.6/5.2
41 6.00.06 5OIR 5.20.02[b] 0.39/4.4/6.9
42 6.50.03 – NA[a] 0.33/4.6/13
43 5.20.06 – 3.70.10[a] 0.30/3.4/10
44 6.90.07 4QXM NA[b] 0.36/3.1/10
45 8.10.27 5JFO 8.00.10[b] 0.40/4.7/9.4
46 6.30.25 5OIS 6.30.10[b] 0.32/3.9/8.8
47 7.30.20 5OIT 7.10.06[a] 0.36/5.1/8.2
[a] Compounds were tested up to 1 mm. [b] Compounds were tested up to 100 mm. [c] LE metrics were calculated using Stradrop in silico prediction soft-
ware. [d] Data previously reported.[14b] [e] Data are the meanSD of one independent experiment performed in duplicate. [f] Data are the meanSD of
two independent experiments, each performed in duplicate. [g] No Kd values are quoted, but some interaction was observed. ND=not determined, NA=
not available.
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Figure 5. FBLG strategies: merging and growing. Figure 7. Design strategy for pyrazoles 46 and 47.
Figure 4. Crystal structures showing novel InhA–NADH–ligand complexes:
A) overlay for fragments 12 (yellow) and 24 (blue), B) merged urea lead 37,
and C) overlay for fragment 40 (blue) and fused lead 41 (yellow). Figure 6. Crystal structures showing novel InhA–NADH–ligand complexes:
A) overlay for fragments 4 (blue) and 9 (yellow), B) overlay of 34 (yellow)
with the published advanced lead 45 (blue; PDB ID: 5JFO), and C) overlay
for fragment 9 (yellow) and lead 46 (blue).
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ments with minimal FGC, relies on FGC implementation, which
is likely to alter binding conformation.[23] This is a common
issue associated with fragment optimization, resulting in struc-
ture–activity relationship disconnections which are often diffi-
cult to interpret. Our findings are also in agreement with the
molecular complexity theory by Hann et al. ,[3, 24] for which mod-
erately complex ligands, like the identified FGC fragment hits,
have a higher probability of a “useful event”, that is the detec-
tion of a unique binding pose. These results reported here pro-
vide support for the rational design, synthesis and screening of
novel diverse fragments with built in functional groups. The
described InhA FB-leads showed good InhA enzymatic activity
as well as ligand efficiency (LE) metrics.[25] Additional optimiza-
tion efforts have resulted in further improved InhA biochemical
as well as Mtb whole cell potency, which will be reported else-
where.
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